Charles M. Rudin

Physician-scientist Charles M. Rudin leads the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC). His research integrates preclinical models like patient-derived xenografts with early-phase clinical trials to develop novel lung cancer therapies, focusing on small cell lung cancer (SCLC) and neuroendocrine transformation. Affiliations include the Molecular Pharmacology Program, Fiona and Stanley Druckenmiller Center for Lung Cancer Research, and Gerstner Sloan Kettering Graduate School of Biomedical Sciences.

• Education: MD, PhD from University of Chicago Pritzker School of Medicine
• Key Research Areas: SCLC therapeutic resistance, neuroendocrine tumor biology, genomic instability (chromothripsis), immunotherapy responsiveness, and tumor plasticity mechanisms

Publications Trends: Recent work emphasizes DLL3 imaging for aggressive tumors, SMARCA4 regulation in cancer subtypes, CD70/CD38 immunotherapy targets, and DNA damage repair pathways as therapeutic vulnerabilities. Collaborative studies span lung, prostate, and neuroendocrine cancers with a focus on cross-tumor type translational applications.

• Key Collaborators: Álvaro Quintanal Villalonga (AstraZeneca), Esther Redin Resano (Lab Co-Director), and alumni like John T. Poirier (NYU) and Benjamin Lok (University of Toronto)
• Lab Members: Graduate students (Fathema Uddin, Vidushi Durani), postdoctoral fellows (Jin Lee, Sohrab Salehi), and research technicians (Rishika Giri)

Disclosures: Rudin has industry affiliations with AbbVie, Amgen, Boehringer Ingelheim, and Earli Inc., reflecting his translational research focus.